Research
Hormonal
Obesity induces chronic low-grade systemic inflammation through adipose tissue-derived cytokines (such as TNF-α, IL-6, and CRP), which accelerates atherosclerosis and increases the risk of cardiovascular disease.
If you have excess body fat, particularly around your midsection, your fat tissue is actively releasing inflammatory chemicals that damage your blood vessels and increase heart disease risk. Managing weight and reducing visceral fat can help lower this chronic inflammation and protect your cardiovascular health.
GoodSupportsHIGH confidence
It was recently suggested that some forms of obesity are associated with chronic low-grade inflammation... It is likely that inflammation induced by obesity accelerates the atherosclerosis.
Why this rating
The paper is a review citing numerous prospective epidemiologic and clinical studies, though it does not present new primary data.
Source
Inflammation, a Link between Obesity and Cardiovascular Disease
Zhaoxia Wang et al. · Mediators of Inflammation · 2010
DOI 10.1155/2010/535918
narrative_reviewCited 413×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Elevated levels of C-reactive protein (CRP) and Serum Amyloid A (SAA) serve as independent predictors of cardiovascular events and are directly linked to obesity-induced inflammation.Strong
- Adiponectin levels decrease in obesity and contribute to cardiovascular risk by failing to provide anti-inflammatory and anti-atherogenic protection to the vessel wall.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →